0000950170-23-070841.txt : 20231215
0000950170-23-070841.hdr.sgml : 20231215
20231215173820
ACCESSION NUMBER: 0000950170-23-070841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231213
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PATOU GARY
CENTRAL INDEX KEY: 0001283535
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36687
FILM NUMBER: 231491552
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001582313
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980661854
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
BUSINESS PHONE: (604) 484-3300
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
4
1
ownership.xml
4
X0508
4
2023-12-13
0001582313
Xenon Pharmaceuticals Inc.
XENE
0001283535
PATOU GARY
200 - 3650 GILMORE WAY
BURNABY
A1
V5G 4W8
BRITISH COLUMBIA, CANADA
true
false
false
false
false
Common Shares
2023-12-13
4
M
false
6378
9.85
A
29951
D
Common Shares
2023-12-13
4
F
false
1278
39.68
D
28673
D
Common Shares
2023-12-13
4
S
false
5100
38.94
D
23573
D
Common Shares
2023-12-13
4
M
false
2880
9.85
A
26453
D
Common Shares
2023-12-13
4
F
false
577
39.68
D
25876
D
Common Shares
2023-12-13
4
S
false
2303
39.10
D
23573
D
Common Shares
2023-12-13
4
M
false
5144
9.00
A
28717
D
Common Shares
2023-12-13
4
F
false
1167
39.68
D
27550
D
Common Shares
2023-12-13
4
S
false
3977
39.84
D
23573
D
Common Shares
2023-12-13
4
S
false
7598
41.05
D
4902
I
See Note
Stock Option (Right to Buy)
9.85
2023-12-13
4
M
false
6378
0
D
2016-12-31
2024-01-13
Common Shares
6378
0
D
Stock Option (Right to Buy)
9.85
2023-12-13
4
M
false
2800
0
D
2016-12-31
2024-01-13
Common Shares
2800
0
D
Stock Option (Right to Buy)
9.00
2023-12-13
4
M
false
5144
0
D
2017-11-04
2024-11-03
Common Shares
5144
0
D
Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.
The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
/s/ Sherry Aulin, Attorney-in-fact
2023-12-15